tetano
Editor, Senior Moderator
Diabetes Metab Syndr
. Nov-Dec 2020;14(6):2177-2183.
doi: 10.1016/j.dsx.2020.11.006. Epub 2020 Nov 11.
The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
Antonia Anna Lukito[SUP] 1 [/SUP], Raymond Pranata[SUP] 2 [/SUP], Joshua Henrina[SUP] 3 [/SUP], Michael Anthonius Lim[SUP] 4 [/SUP], Sherly Lawrensia[SUP] 5 [/SUP], Ketut Suastika[SUP] 6 [/SUP]
Affiliations
Abstract
Background and aims: Diabetes is one of the most common comorbidities, and it is associated with poorer outcomes in patients with coronavirus disease 2019 (COVID-19). Preliminary findings showed that mortality was reduced in those who consume metformin compared to those who did not, and given its low cost and widespread availability; metformin is an attractive and potential agent to mitigate excessive risk in diabetic populations.
Methods: Several medical databases (Pubmed, EuropePMC, EBSCOhost, Proquest, Cochrane library) and two health-science preprint servers (preprint.org and Medrxiv) were systematically searched for relevant literature.
Results: Nine studies with 10,233 subjects were included in the qualitative and quantitative synthesis. Meta-analysis showed that metformin is associated with lower mortality in pooled non-adjusted model (OR 0.45 [0.25, 0.81], p = 0.008; I[SUP]2:[/SUP] 63.9%, p = 0.026) and pooled adjusted model (OR 0.64 [0.43, 0.97], p = 0.035; I[SUP]2[/SUP]: 52.1%, p = 0.064).
Conclusion: The analysis showed that metformin consumption was associated with lower mortality. Randomized controlled trials are needed to confirm this finding.
Keywords: COVID-19; Diabetes melitus; Metformin; Mortality; SARS-CoV-2.
. Nov-Dec 2020;14(6):2177-2183.
doi: 10.1016/j.dsx.2020.11.006. Epub 2020 Nov 11.
The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
Antonia Anna Lukito[SUP] 1 [/SUP], Raymond Pranata[SUP] 2 [/SUP], Joshua Henrina[SUP] 3 [/SUP], Michael Anthonius Lim[SUP] 4 [/SUP], Sherly Lawrensia[SUP] 5 [/SUP], Ketut Suastika[SUP] 6 [/SUP]
Affiliations
- PMID: 33395778
- DOI: 10.1016/j.dsx.2020.11.006
Abstract
Background and aims: Diabetes is one of the most common comorbidities, and it is associated with poorer outcomes in patients with coronavirus disease 2019 (COVID-19). Preliminary findings showed that mortality was reduced in those who consume metformin compared to those who did not, and given its low cost and widespread availability; metformin is an attractive and potential agent to mitigate excessive risk in diabetic populations.
Methods: Several medical databases (Pubmed, EuropePMC, EBSCOhost, Proquest, Cochrane library) and two health-science preprint servers (preprint.org and Medrxiv) were systematically searched for relevant literature.
Results: Nine studies with 10,233 subjects were included in the qualitative and quantitative synthesis. Meta-analysis showed that metformin is associated with lower mortality in pooled non-adjusted model (OR 0.45 [0.25, 0.81], p = 0.008; I[SUP]2:[/SUP] 63.9%, p = 0.026) and pooled adjusted model (OR 0.64 [0.43, 0.97], p = 0.035; I[SUP]2[/SUP]: 52.1%, p = 0.064).
Conclusion: The analysis showed that metformin consumption was associated with lower mortality. Randomized controlled trials are needed to confirm this finding.
Keywords: COVID-19; Diabetes melitus; Metformin; Mortality; SARS-CoV-2.